Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 242

Dr Lorenz Truemper - Georg August University, Göttingen, Germany

Dr Lorenz Truemper speaks to ecancer at ASH 2018 about the study of brentuximab vedotin and CHP versus CHOP in the treatment for peripheral T-Cell lymphoma patients.

He explains that brentuximab vedotin targets the CD30 antigen that is very specific to T-Cell lymphomas.

Dr Truemper reports that the treatment with brentuximab vedotin has already provided a superior strong difference in progression free survival.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation